Abstract:Study objective: Recommendations regarding vancomycin dosing in critically ill patients on continuous venovenous hemofiltration (CVVH) are limited. The purpose of this study was to evaluate current dosing practices of pharmacists for patients treated with CVVH, develop guidelines for optimal dosing and monitoring of vancomycin to improve target trough attainment, and reduce pharmacist workload. Design: A retrospective cohort study. was performed of critically ill adult patients from January 2015 to December 2018. Patients were included if they received vancomycin during CVVH for at least 48 h. Patients with significant residual kidney function, defined as daily urine output >400 ml or significant fluctuations (≥1000 ml/h in a 24-h period) in their hemofiltration rates, were excluded. Interruptions in CVVH up to 6 h/day were permitted. Dosing strategies with two dosing categories were defined: (1) dosing based on random serum levels (dosing by level, DBL) or (2) scheduled vancomycin dosing (SD). Setting: Academic medical center in Detroit, Michigan. Patients: Critically ill adult patients. Measurements and main results: During the study period, 942 patients were evaluated and 200 met inclusion criteria, for a total of 586 serum vancomycin levels. There were 141 patients with 443 random vancomycin serum levels in the DBL group and 59 patients with143 vancomycin trough levels in the SD group. Mean vancomycin trough levels were similar between groups (17.1 ± 6 vs. 16.5 ± 4 mcg/ml) for the DBL and SD groups, respectively. For the primary end point of overall target trough achievement of 15-20 mcg/ml, significantly more trough levels in the SD group were in the 15-20 mcg/ml range compared with the DBL group, 50% vs. 38%; p < 0.001, respectively. When target trough range was extended to 10-20 mcg/ml, success rates were similar between groups (74% DBL vs. 82% SD, p = 0.021). The number of interventions required by the pharmacist, including notes per day and orders per day, were reduced by approximately 50% when the SD strategy was utilized. Scheduled vancomycin dosing regimens of 15-22 mg/kg every 12-24 h were required to yield trough levels in the 15-20 mcg/ml range. Conclusions: Target vancomycin trough achievement of 15-20 mcg/ml occurred more frequently when vancomycin was scheduled at a dose of 15-22 mg/kg every 12-24 h based on ultrafiltration rate and may alleviate the time and cost associated with frequent vancomycin serum monitoring.

Determination of serum linezolid concentration in critically ill patients during continuous veno-venous hemofiltration

Therapy drug monitoring of linezolid in serum of critically ill patients

Therapy Drug Monitoring of Linezolid in Serum of Critically Ⅲ Patients

HPLC determination and clinical application of linezolid concentration in human serum

Concentration Determination of Linezolid in Human Serum of Patients with Severe Infections and Evaluation of Clinical Application

Validation of a fast and reliable liquid chromatography tandem mass spectrometry for simultaneous quantitation of Voriconazole, Posaconazole and Linezolid in human serum

Effects of continuous venovenous hemofiltration on vancomycin trough concentrations in critically ill children

Determination and Clinical Application of Linezolid in Human Plasma by LC-MS/MS and HPLC

Pharmacokinetics and Pharmacodynamics of Linezolid in Patients with Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration

Determination the Concentration of Linezolid in Human Plasma by HPLC-MS/MS

Simultaneous Determination of Linezolid and Voriconazole Serum Concentrations Using Liquid Chromatography-Tandem Mass Spectrometry

A Systematic Review of Linezolid Pharmacokinetics/Pharmacodynamics in Patients Undergoing Continuous Renal Replacement Therapy: Does One Size Fit All?

Therapeutic drug monitoring of linezolid: HPLC-based assays for routine quantification of linezolid in human serum and cerebrospinal fluid

Determination of linezolid in human plasma by LC-MS/MS

Evaluation of dosing strategies and trough concentrations of vancomycin in patients undergoing continuous venovenous hemofiltration

Determination of teicoplanin serum concentration in critically ill patients

Effect of the Application of Continuous Cenous Venous Hemofiltration on Pulmonary Vascular Permeability in the Early Stage of Septic Shock

Clinical Analysis of Continuous Venovenous Hemofiltration in Patients with Severe Congestive Heart Failure

Determinants of Vancomycin Trough Concentration in Patients Receiving Continuous Veno-Venous Hemodialysis

Novel method for determination of colistin sulfate in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its clinical applications in critically ill patients

Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis